DOCSLIB.ORG

Hematopoietic Growth Factors How Long After Neutrophil Recovery Should Myeloid Growth Factors Be Continued in Autologous Hematop

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Hematopoietic Growth Factors How Long After Neutrophil Recovery Should Myeloid Growth Factors Be Continued in Autologous Hematop Bone Marrow Transplantation (2004) 33, 715–719 & 2004 Nature Publishing Group All rights reserved 0268-3369/04 $25.00 www.nature.com/bmt Hematopoietic growth factors How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? A Verma, J Pedicano, S Trifilio, S Singhal, M Tallman, J Winter, S Williams, L Gordon, J Monreal and J Mehta Hematopoietic Stem Cell Transplant Program, Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA Summary: The traditional definition of myeloid engraftment has been the first of 3 consecutive days with an absolute Growth factors are routinely used after autotransplanta- neutrophil count (ANC) of 0.5 Â 109/l or more, to ensure tion to accelerate hematopoietic recovery, and are sustained recovery. Thus, growth factors are usually continued until the absolute neutrophil count (ANC) is continued until ANC is X0.5 Â 109/l for 3 consecutive X0.5 Â 109/l on 3 consecutive days. Since ANCoften days. We have shown that the neutrophil count almost increases to very high levels with this strategy, we never declines below 0.5 Â 109/l on the 2 consecutive days discontinued growth factor on the first day ANCreached after having reached that level in blood stem cell autograft8 0.5 Â 109/l in 45 patients (Study Group), and compared and allograft9 recipients. Based upon this, we modified our their subsequent ANCto 108 historic controls who definition of myeloid engraftment to the first day with ANC received growth factor longer. While ANCon the day X0.5 Â 109/l; a change that is associated with some logistic after reaching 0.5 Â 109/l was comparable between benefits.8 At the same time, since the ANC actually groups, ANCon the third day was significantly higher in increased several-fold over the 2–3 days following the day the Control Group (2.3 vs 4.9 Â 109/l; P ¼ 0.0003). When of engraftment after autograft,8 we changed our routine compared to the first day, ANCin the Study Group was clinical practice to discontinuing growth factor the day the higher by a median of 140% on the third day and by ANC reached 0.5 Â 109/l rather than continuing for an 450% in the Control Group (P ¼ 0.0002). A significantly additional 2 days. higher proportion of patients experienced a decline in This retrospective analysis was undertaken to compare ANCafter the first day in the Study Group. However, the course of neutrophil recovery in patients who discon- only one patient in the Study Group became neutropenic tinued growth factor, with those who continued growth transiently and ANCrecovered spontaneously the next factor after the first day with ANC X0.5 Â 109/l. day. The incidence of fever and hospitalization were comparable. We conclude that growth factors can be discontinued after autotransplantation the day the ANC Patients and methods reaches 0.5 Â 109/l, without compromising neutrophil recovery. A total of 153 adult patients with malignant diseases Bone Marrow Transplantation (2004) 33, 715–719. autografted in the Hematopoietic Stem Cell Transplant doi:10.1038/sj.bmt.1704415 Program of the Division of Hematology-Oncology of the Published online 26 January 2004 Feinberg School of Medicine, Northwestern University, Keywords: autologous hematopoietic stem cell transplan- and the Northwestern Memorial Hospital between Febru- tation; engraftment; filgrastim; neutropenia; sargramostim ary 1998 and January 2003 were studied. All patients provided informed consent for the transplant procedures, and all research protocols were approved by the Institu- Myeloid colony-stimulating factors such as filgrastim (G- tional Review Board. CSF) and molgramostim (GM-CSF) are routinely used Electronic and paper records were reviewed to obtain all after autotransplantation to hasten neutrophil recovery.1,2 blood counts, whether performed in the hospital laboratory Growth factors are typically started as early as day 0 or as (in-patient), the clinic laboratory (outpatient), or elsewhere late as day 7, and are continued until neutrophil recovery.3–7 (usually immediately after discharge through home health Therefore, the duration of growth factor administration is agency services). Whenever multiple blood count results usually related to the definition of myeloid engraftment. were available for the same day, the morning blood count was included in the analysis and the remaining counts were not studied. ANC included segmented neutrophils as well as bands. Correspondence: Dr J Mehta, 676 N. St Clair Street, Suite 850, Chicago, IL 60611, USA; E-mail: [email protected] Table 1 shows the patient characteristics. The condition- Received 09 July 2003; accepted 07October 2003 ing regimens employed were at standard doses, and Published online 26 January 2004 included high-dose melphalan (plasma cell dyscrasias), Growth factor duration A Verma et al 716 busulfan-etoposide (acute myeloid leukemia), busulfan- (1–4), and were compared to the Study Group (n ¼ 45), cyclophosphamide (lymphoma), carmustine-etoposide-cy- which received no growth factor after ANC reached tarabine-melphalan (BEAM) (lymphoma, Hodgkin’s dis- 0.5 Â 109/l. The two groups were compared using the ease), cyclophosphamide-carboplatin-etoposide with total- Wilcoxon rank-sum test for continuous variables, and the lymphoid irradiation (Hodgkin’s disease), or cyclopho- w2 test or the Fisher’s exact test for categoric variables. sphamide-carboplatin-thiotepa (breast cancer). CD34 þ cell doses were calculated on the basis of the ideal body weight (IBW).10 Patients did not receive trimethoprim- Results sulfamethoxazole routinely in the immediate post trans- plant period. As Table 1 shows, there were some differences between groups. There was a significantly higher proportion Growth factor administration of myeloma patients and GM-CSF recipients in those stopping growth factors early. A significantly higher After the transplant, 136 patients received filgrastim (G- proportion of Study Group patients started the growth CSF) and 17patients received sargramostim (GM-CSF) at factor later. The CD34 cell dose was slightly higher the dose of 5–10 mg/kg, subcutaneously daily, until the þ and engraftment slightly slower for those stopping ANC reached 0.5 Â 109/l, the first day with ANC growth factor early, but these differences were not X0.5 Â 109/l being considered the day of engraftment. statistically significant. The actual growth factor doses The type of growth factor used, unless dictated by a used were comparable for both groups. All GM-CSF particular protocol, was at the discretion of the physician. recipients received 500 mg of the drug. G-CSF recipients in The growth factor dose was usually rounded off to the both groups received a median of 480 mg G-CSF (range nearest vial size to avoid wastage. Growth factors were 300–780). usually administered in the late afternoon or evening. Table 2 and Figure 1 illustrate the patterns of neutrophil Growth factor was discontinued when the ANC reached recovery. ANC was higher in the Study Group on the day 0.5 Â 109/l in 45 patients, all treated since May 2002. The of engraftment, but higher in the Control Group on the last dose of growth factor in these patients was the evening subsequent 2 days. The difference was particularly marked before ANC reached this threshold, and they did on the third day. The magnitude of ANC increase was also not receive any growth factor once ANC reached the greater in the Control Group. A significantly greater threshold. The remaining patients continued growth factor proportion of Study Group patients experienced a decline until ANC was X0.5 Â 109/l on 2 consecutive days (an in ANC on the second and third days. However, only in additional day of growth factor; n ¼ 37), on 3 consecutive days (2 additional days of growth factor; n ¼ 30), or 4–5 consecutive days (3–4 additional days of growth factor; n ¼ 41). Most of these patients were treated prior Table 1 Patient characteristics to May 2002. No growth factor after Growth factor after P All patients other than the 45 stopping the growth factor ANC 40.5 Â 109/l ANC 40.5 Â 109/l early were to have received 2 additional days of growth (Study Group) (Control Group) factor after reaching ANC X0.5 Â 109/l, allowing for 9 n 45 108 documentation of ANC X0.5 Â 10 /l for 3 consecutive Age (years) 53 (27–69) 53 (22–70) 0.89 days. However, this was not the case for two reasons. Those Male sex 25 (55%) 50 (45%) 0.29 stopping the growth factor after 1 additional day (n ¼ 37) did so mostly because an additional intra-day blood count Diagnosis 0.006 9 Acute leukemia 6 (13%) 10 (9%) done on the day ANC reached 0.5 Â 10 /l showed a further Lymphoma 16 (36%) 54 (50%) increase in ANC. Thus, the growth factor was stopped the Plasma cell 23 (51%) 30 (28%) next day after seeing a third consecutive ANC count (rather disorders than the third consecutive day) X0.5 Â 109/l. Those Other 0 (0%) 14 (13%) continuing growth factor beyond the planned 2 additional CD34+ cell dose days (n ¼ 41) usually did so for one of two reasons. For 106/kg IBW 5.4 (1.8–22.9) 4.2 (1.0–27.8) 0.10 some hospitalized patients, the order to discontinue growth o2 Â 106/kg 2 (4%) 9 (8%) 0.51 factor automatically on the third day of ANC X0.5 Â 109/l, IBW written as part of the routine admission order set, did not Growth factor 0.001 get implemented on the correct day. For some discharged G-CSF 34 (76%) 102 (94%) patients, Home Health nurses or the patients themselves GM-CSF 11 (24%) 6 (6%) continued administering growth factor when it should have been stopped.
Load more

Recommended publications
  • Pearls of Laboratory Medicine Transcript Document
    Pearls of Laboratory Medicine www.traineecouncil.org TITLE: Transfusion Support in Hematopoietic Stem Cell Transplant PRESENTER: Erin K. Meyer, DO, MPH Slide 1: Title Slide Hello, my name is Erin Meyer. I am the medical director of apheresis and associate medical director of Transfusion Services at Nationwide Children’s Hospital in Columbus Ohio. Welcome to this Pearl of Laboratory Medicine on “Transfusion Support in Hematopoietic Stem Cell Transplant or HSCT.” Slide 2: Transfusion Support for Hematopoietic Stem Cell Transplant (HSCT) The objectives of my talk are a brief overview of the different types of HSCT followed by a review of the sources of HSCT available and transfusion thresholds for patients receiving the different types of HSCT. Finally, I will discuss ABO-incompatible HSCT with a focus on the complications of and transfusion support for each possible ABO-incompatible combination. Hematopoietic stem cells came to light after the dropping of the atomic bombs in 1945. People who survived the initial explosions later died of bone marrow failure from radiation. A series of sentinel experiments by Till and McCulloch in the 1960s then showed that transfer of bone marrow cells from donor mice into lethally irradiated recipient mice resulted in the formation of colonies of myeloid, erythroid, and megakaryocytic cells in the recipient’s spleen approximately 7-14 days later. Stem cells have two very unique properties: the ability to self-renew and the ability to regenerate. The field of stem cell biology has only grown and HSCTs are able to be transplanted now to recipients to help a variety of diseases.
    [Show full text]
  • Hematopoietic Stem Cell Therapy) in MS
    FAQ About HSCT (Hematopoietic Stem Cell Therapy) in MS There is growing evidence that autologous HSCT is not for everyone with MS but may be highly effective for people with relapsing MS who meet very specific characteristics. The National Medical Advisory Committee of the National MS Society has written an article reviewing evidence related to the optimal use of autologous hematopoietic stem cell transplantation (aHSCT, commonly known as bone marrow transplants) for the treatment of specific types of relapsing multiple sclerosis. The committee’s findings are published in JAMA Neurology (online October 26, 2020). Q. What is HSCT for multiple sclerosis? A. HSCT (Hematopoietic Stem Cell Transplantation) attempts to “reboot” the immune system, which is responsible for damaging the brain and spinal cord in MS. In HSCT for MS, hematopoietic (blood cell-producing) stem cells, which are derived from a person’s own (“autologous”) bone marrow or blood, are collected and stored, and the rest of the individual’s immune cells are depleted by chemotherapy. Then the stored hematopoietic stem cells are reintroduced to the body. The new stem cells migrate to the bone marrow and over time produce new white blood cells. Eventually they repopulate the body with immune cells. Q. What is the idea behind autologous HSCT (aHSCT) for MS? A. The goal of aHSCT is to reset the immune system and stop the inflammation that contributes to active relapsing MS. Q. Is aHSCT an FDA-approved therapy option for people with MS? A. The medications and procedures used in aHSCT are already approved by the FDA. Publication of the outcomes from well-controlled clinical studies of aHSCT therapy will encourage greater acceptance and use by the medical community.
    [Show full text]
  • IDF Guide to Hematopoietic Stem Cell Transplantation
    Guide to Hematopoietic Stem Cell Transplantation Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation This publication contains general medical information that cannot be applied safely to any individual case. Medical knowledge and practice can change rapidly. Therefore, this publication should not be used as a substitute for professional medical advice. In all cases, patients and caregivers should consult their healthcare providers. Each patient’s condition and treatment are unique. Copyright 2018 by Immune Deficiency Foundation, USA Readers may redistribute this guide to other individuals for non-commercial use, provided that the text, html codes, and this notice remain intact and unaltered in any way. Immune Deficiency Foundation Guide to Hematopoietic Stem Cell Transplantation may not be resold, reprinted or redistributed for compensation of any kind without prior written permission from the Immune Deficiency Foundation (IDF). If you have any questions about permission, please contact: Immune Deficiency Foundation, 110 West Road, Suite 300, Towson, MD 21204, USA, or by telephone: 800-296-4433. For more information about IDF, go to: www.primaryimmune.org. This publication has been made possible through the IDF SCID Initiative and the SCID, Angels for Life Foundation. Acknowledgements The Immune Deficiency Foundation would like to thank the organizations and individuals who helped make this publication possible and contributed to the development of the Immune Deficiency Foundation Guide to Hematopoietic Stem
    [Show full text]
  • Stem Cell Hematopoiesis
    Hematopoietic and Lymphoid Neoplasm Project Introduction to the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 4th edition 2 Hematopoietic and Lymphoid Lineages, Part I Steven Peace, CTR Westat September 2009 3 Objectives • Understand stem cell hematopoiesis • Understand proliferation • Understand differentiation • Provide a History of Classification of Tumors of Hematopoietic and Lymphoid Tissues • Understand the delineation of cell lines (lineage) in relation to the WHO Classification 4 Objectives (2) • Introduce WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th ed. • Introduce NEW ICD-O histology codes • Introduce NEW reportable conditions 5 Stem Cell Hematopoiesis • What is a hematopoietic stem cell? • Where are hematopoietic stem cells found? • What is Hematopoiesis? • Hematopoietic stem cells give rise to ALL blood cell types including; • Myeloid lineages • Lymphoid lineages 6 Hematopoietic stem cells give rise to two major progenitor cell lineages, myeloid and lymphoid progenitors Regenerative Medicine, 2006. http://www.dentalarticles.com/images/hematopoiesis.png 7 Proliferation and Differentiation • Regulation of proliferation • Regulation of differentiation • Both affect development along cell line • Turn on/Turn off • Growth factors • Genes (including mutations) • Proteins • Ongogenesis – becoming malignant 8 Blood Lines – Donald Metcalf, AlphaMED Press, 2005 Figure 3.2 The eight major hematopoietic lineages generated by self-renewing multipotential stem cellsB Copyright © 2008 by AlphaMed
    [Show full text]
  • Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S
    bioRxiv preprint doi: https://doi.org/10.1101/503813; this version posted January 15, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Cell Division History Determines Hematopoietic Stem Cell Potency Fumio Arai1,†,*, Patrick S. Stumpf2,†, Yoshiko M. Ikushima3,†, Kentaro Hosokawa1, Aline Roch4, Matthias P. Lutolf4, Toshio Suda5, and Ben D. MacArthur2,6,7,* †† 1Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, 812-8582, Fukuoka, Japan. 2Centre for Human Development, Stem Cells and Regeneration, University of Southampton, SO17 1BJ, UK 3Research Institute National Center for Global Health and Medicine, Tokyo, Japan 4Laboratory of Stem Cell Bioengineering, Institute of Bioengineering, School of Life Sciences and School of Engineering, Ecole Polytechnique Federale de Lausanne (EPFL), CH-1015 Lausanne, Switzerland 5Cancer Science Institute, National University of Singapore, 14 Medical Drive, MD6, 117599 Singapore, Singapore 6Institute for Life Sciences, University of Southampton, SO17 1BJ, United Kingdom 7Mathematical Sciences, University of Southampton, SO17 1BJ, United Kingdom *Correspondence to Fumio Arai ([email protected]) and Ben MacArthur ([email protected]) †These authors contributed equally. ††Lead Author ABSTRACT Loss of stem cell self-renewal may underpin aging. Here, we combined single cell profiling, deep-learning, mathematical modelling and in vivo functional studies to explore how hematopoietic stem cell (HSC) division patterns evolve with age. We trained an artificial neural network (ANN) to accurately identify cell types in the hematopoietic hierarchy and predict their age from their gene expression patterns.
    [Show full text]
  • Differential Contributions of Haematopoietic Stem Cells to Foetal and Adult Haematopoiesis: Insights from Functional Analysis of Transcriptional Regulators
    Oncogene (2007) 26, 6750–6765 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Differential contributions of haematopoietic stem cells to foetal and adult haematopoiesis: insights from functional analysis of transcriptional regulators C Pina and T Enver MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK An increasing number of molecules have been identified ment and appropriate differentiation down the various as candidate regulators of stem cell fates through their lineages. involvement in leukaemia or via post-genomic gene dis- In the adult organism, HSC give rise to differentiated covery approaches.A full understanding of the function progeny following a series of relatively well-defined steps of these molecules requires (1) detailed knowledge of during the course of which cells lose proliferative the gene networks in which they participate and (2) an potential and multilineage differentiation capacity and appreciation of how these networks vary as cells progress progressively acquire characteristics of terminally differ- through the haematopoietic cell hierarchy.An additional entiated mature cells (reviewed in Kondo et al., 2003). layer of complexity is added by the occurrence of different As depicted in Figure 1, the more primitive cells in the haematopoietic cell hierarchies at different stages of haematopoietic differentiation hierarchy are long-term ontogeny.Beyond these issues of cell context dependence, repopulating HSC (LT-HSC),
    [Show full text]
  • Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S
    Knowledge of transfusion complications related to HSCT can help with the early detection and treatment of patients before and after transplantation. Ray Paul. SP12-6796 × 40, 2013. Acrylic, latex, enamel on canvas printed with an image of myxofibrosarcoma with metastases to the artist’s lung, 26" × 36". Transfusion Support Issues in Hematopoietic Stem Cell Transplantation Claudia S. Cohn, MD, PhD Background: Patients receiving hematopoietic stem cell transplantation require extensive transfusion support until red blood cell and platelet engraftment occurs. Rare but predictable complications may arise when the transplanted stem cells are incompatible with the native ABO type of the patient. Immediate and delayed hemolysis is often seen. Methods: A literature review was performed and the results from peer-reviewed papers that contained reproducible findings were integrated. Results: A strong body of clinical evidence has developed around the common complications experienced with ABO-incompatible hematopoietic stem cell transplantation. These complications are discussed and the underlying pathophysiology is explained. General treatment options and guidelines are enumerated. Conclusions: ABO-incompatible hematopoietic stem cell transplantations are frequently performed. Immune-related hemolysis is a commonly encountered complication; therefore, health care professionals must recognize the signs of immune-mediated hemolysis and understand the various etiologies that may drive the process. Introduction antigen (HLA) matching remains an important predic- Hematopoietic stem cell transplantation (HSCT) is used tor of success with HSCT; however, the ABO barrier is to treat a variety of hematological and congenital diseas- often crossed when searching for the most appropriate es. The duration and specificity of transfusion support HLA match between donor and patient.
    [Show full text]
  • Stem-Cell Transplant Acute Myeloid Leukemia, 11A-2
    NC Medicaid Medicaid and Health Choice Hematopoietic Stem-Cell Clinical Coverage Policy No: 11A-2 Transplantation for Amended Date: July 1, 2021 Acute Myeloid Leukemia (AML) To all beneficiaries enrolled in a Prepaid Health Plan (PHP): for questions about benefits and services available on or after implementation, please contact your PHP. Table of Contents 1.0 Description of the Procedure, Product, or Service ........................................................................... 1 1.1 Definitions .......................................................................................................................... 4 1.1.1 Donor Lymphocyte Infusion (DLI) ....................................................................... 4 2.0 Eligibility Requirements .................................................................................................................. 4 2.1 Provisions............................................................................................................................ 4 2.1.1 General ................................................................................................................... 4 2.1.2 Specific .................................................................................................................. 5 2.2 Special Provisions ............................................................................................................... 5 2.2.1 EPSDT Special Provision: Exception to Policy Limitations for a Medicaid Beneficiary under 21 Years of Age ......................................................................
    [Show full text]
  • Quiescence and Self-Renewal Hematopoietic Stem Cell Status
    The Endothelial Antigen ESAM Monitors Hematopoietic Stem Cell Status between Quiescence and Self-Renewal This information is current as Takao Sudo, Takafumi Yokota, Kenji Oritani, Yusuke of October 2, 2021. Satoh, Tatsuki Sugiyama, Tatsuro Ishida, Hirohiko Shibayama, Sachiko Ezoe, Natsuko Fujita, Hirokazu Tanaka, Tetsuo Maeda, Takashi Nagasawa and Yuzuru Kanakura J Immunol 2012; 189:200-210; Prepublished online 30 May 2012; doi: 10.4049/jimmunol.1200056 Downloaded from http://www.jimmunol.org/content/189/1/200 Supplementary http://www.jimmunol.org/content/suppl/2012/05/30/jimmunol.120005 http://www.jimmunol.org/ Material 6.DC1 References This article cites 57 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/189/1/200.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American
    [Show full text]
  • The Number of Nucleated Cells Reflects the Hematopoietic Content of Umbilical Cord Blood for Transplantation
    Bone Marrow Transplantation, (1999) 24, 965–970 1999 Stockton Press All rights reserved 0268–3369/99 $15.00 http://www.stockton-press.co.uk/bmt The number of nucleated cells reflects the hematopoietic content of umbilical cord blood for transplantation FTH Lim1,2, JM v Beckhoven3, A Brand3, JC Kluin-Nelemans1, JMH Hermans4, R Willemze1, HHH Kanhai2 and JHF Falkenburg1 Departments of 1Hematology, 2Obstetrics and 4Medical Statistics from the Leiden University Medical Center; and 3Red Cross Blood Bank, Leidsenhage, The Netherlands Summary: irradiated recipients. Since the colony-forming unit granulocyte–monocyte (CFU-GM) defined in a semi-solid A single umbilical cord blood (UCB) collection may con- culture assay, has been associated with hematopoietic tain sufficient hematopoietic stem cells to achieve engraftment of human bone marrow cells, this assay has engraftment and repopulation of the hematopoietic sys- been used as a quality control method for hematopoietic tem of children and adults after myeloablative therapy. stem cell grafts.12,13 The hematopoietic potential of a UCB unit is often The human hematopoietic stem cells reside in the frac- defined by the number of CD34+ cells or the number of tion of cells expressing the CD34 antigen.14,15 CD34+ cells colony-forming units as measured in semisolid hemato- can be identified by flow cytometry, but the various tech- poietic progenitor cell (HPC) cultures. However, these niques for CD34 enumeration that have been advocated assays are relatively difficult to standardize between may result in different estimated concentrations.16–18 Both UCB banks. The number of nucleated cells infused per the CD34+ cell content, and the numbers of hematopoietic kilogram body weight of the recipient is also reported progenitor cells (HPC) as determined in semi-solid medium to be a significant factor in the speed of recovery of culture assays are frequently used to predict the hematopoi- neutrophils and platelets after transplantation.
    [Show full text]
  • Hematopoiesis Hematopoietic Stem Cells in Adult AML1/Runx1 Negatively Regulates Quiescent
    AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis This information is current as Motoshi Ichikawa, Susumu Goyama, Takashi Asai, Masahito of September 28, 2021. Kawazu, Masahiro Nakagawa, Masataka Takeshita, Shigeru Chiba, Seishi Ogawa and Mineo Kurokawa J Immunol 2008; 180:4402-4408; ; doi: 10.4049/jimmunol.180.7.4402 http://www.jimmunol.org/content/180/7/4402 Downloaded from References This article cites 37 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/180/7/4402.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 28, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis1 Motoshi Ichikawa, Susumu Goyama, Takashi Asai, Masahito Kawazu, Masahiro Nakagawa, Masataka Takeshita, Shigeru Chiba, Seishi Ogawa, and Mineo Kurokawa2 Transcription factor AML1/Runx1, initially isolated from the t(8;21) chromosomal translocation in human leukemia, is essential for the development of multilineage hematopoiesis in mouse embryos.
    [Show full text]
  • Hematopoietic Developmental Pathways: on Cellular Basis
    Oncogene (2007) 26, 6687–6696 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Hematopoietic developmental pathways: on cellular basis H Iwasaki1 and K Akashi1,2 1Center for Cellular and Molecular Medicine, Kyushu University Hospital, Fukuoka, Japan and 2Department of Cancer Immunology and AIDS, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA, USA To elucidate the molecular mechanisms underlying normal counterpart, the common myeloid progenitor (CMP) and malignant hematopoietic development, it is critical to that can be a source of all myeloid cell types, supports identify developmental intermediates for each lineage the concept that lymphoid and myeloid lineages develop downstream of hematopoietic stem cells. Recent advances independently downstream of HSCs (Kondo et al., 1997; in prospective isolation of hematopoietic stem and Akashi et al., 2000). progenitor cells, and efficient xenogeneic transplantation Recent progresses in the fluorescence-activated cell systems have provided a detailed developmental map in sorting analysis using additional surface markers for both mouse and human hematopoiesis, demonstrating that early hematopoiesis, however, have provided more surface phenotypes of mouse stem–progenitor cells and detailed developmental map downstream of HSCs. their human counterparts are considerably different. Importantly, prior to proceed into the classical myeloid Here, we summarize the phenotype and functional vs lymphoid pathways, HSCs appear to form myelo- properties and their differences of hematopoietic stem erythroid vs myelo-lymphoid progenitors (Arinobu and progenitor cell populations between mouse and et al., 2007). Furthermore, it is now clear that there human. are considerable differences in distribution of surface Oncogene (2007) 26, 6687–6696; doi:10.1038/sj.onc.1210754 markers between human and mouse hematopoiesis, which makes identification of human counterparts of Keywords: hematopoietic stem cell; lineage commitment; mouse progenitors difficult.
    [Show full text]